Work

Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.11009

Authors: Chandrajit P. Raut, N. Joseph Espat, Robert G. Maki, Dejka M. Araujo, Toni Faith Williams, Johannes E. Wolff, Ronald P. DeMatteo

Institutions: Brigham and Women's Hospital, Harvard University, Boston University, Northwell Health, Cold Spring Harbor Laboratory, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2760884196

Cites:

Cited by: 14

Related to: 10